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The effects of TRT on these abnormalities are not entirely 
clear.
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Introduction
The Klinefelter syndrome (KS) was, for the first time, 
described in 1942 by Klinefelter as a male clinical syn-
drome characterized by gynecomastia, facial and body hair 
rarefaction, small testicles and infertility [1]. In 1959, this 
condition was associated with the presence of an extra X 
chromosome in the karyotype. The classic form of KS is 
indeed characterized by a 47, XXY karyotype and it rep-
resents about 90% of the cases. The remaining 10% of the 
cases consists of mosaicisms (karyotype 46,XY/47,XXY) 
and other uncommon form of aneuploidies, as 48, XXXY e 
48, XXYY [2].
As regards to the prevalence of KS in the newborn, it 
is about 0.1–0.2%, but it increases to 3–4% if we consider 
the infertile population, and up to 10–12% in azoospermic 
patients [2]. The incidence of this condition has been esti-
mated to be present in 1:500 to 1:1000 men [3].
KS is actually the most common genetic cause of human 
male infertility, but many cases remain undiagnosed 
because these patients often do not present clinical or phe-
notypic abnormalities. However, it is associated with much 
comorbidity that may cause serious consequences. The aim 
of this review is to investigate cardiovascular and metabolic 
disorders present in patients with KS.
Abstract Klinefelter syndrome (KS) is one of the most 
common genetic causes of male infertility. This condition 
is associated with much comorbidity and with a lower life 
expectancy. The aim of this review is to explore more in 
depth cardiovascular and metabolic disorders associated to 
KS. KS patients have an increased risk of cerebrovascular 
disease (standardized mortality ratio, SMR, 2.2; 95% con-
fidence interval, CI, 1.6–3.0), but it is not clear whether the 
cause of the death is of thrombotic or hemorrhagic nature. 
Cardiovascular congenital anomalies (SMR, 7.3; 95% CI, 
2.4–17.1) and the development of thrombosis or leg ulcers 
(SMR, 7.9; 95% CI, 2.9–17.2) are also more frequent in 
these subjects. Moreover, cardiovascular abnormalities may 
be at least partially reversed by testosterone replacement 
therapy (TRT). KS patients have also an increased prob-
ability of endocrine and/or metabolic disease, especially 
obesity, metabolic syndrome and type 2 diabetes mellitus. 
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Klinefelter syndrome: comorbidities and mortality 
rate
It is well known that patients with KS have an increased 
risk of being hospitalized (>70%), and they are more sus-
ceptible to congenital malformations, cardiovascular dis-
eases, psychiatric syndromes, and endocrine/metabolic 
disorders, compared to subjects of the same age (Table 1) 
[4]. The above-mentioned comorbidities are considered 
the most important factors that negatively influence the life 
expectancy of KS patients, whereas socioeconomic fac-
tors seem to play a less significant role [5]. As a result, the 
expected lifespan seems to be lower in patients with KS [4, 
6–8].
Swerdlow and colleagues reported a significant increase 
of the mortality rate in 646 KS patients because of diabe-
tes and cardiovascular diseases [9]. In a subsequent study, 
these authors consistently reported that the mortality rate 
was increased by 50% in 3518 patients who had been diag-
nosed with KS from 1959 until mid-2003 [7]. A lower life 
expectancy was even found in a cohort of 532 subjects 
with KS recorded in a register of patients with chromo-
some abnormalities, instituted in Edinburgh in 1959. These 
cases, notified from all parts of UK (mainly from Scotland 
and Northern England), were followed-up from their inclu-
sion in the registry. The analysis of this cohort showed that 
the median survival was lower by about 5 years [10]. More 
recent registry-based studies reported a median survival 
lower than 2.1 years in KS patients [4, 6–8]. The lower life 
expectancy does not seem to relate to the karyotype, given 
that no significant differences were found between patients 
with classical KS (47, XXY) and those with mosaicism 
(46,XY/47, XXY) or those with karyotypes with more than 
one extra X chromosome [6].
Klinefelter syndrome and cardiovascular risk
Bojesen and colleagues, analyzing a cohort of 4865 sub-
jects, composed by 832 KS and 4033 controls, reported 
that KS patients more frequently had ischemic heart dis-
ease (standardized mortality ratio, SMR, 0.7; 95% confi-
dence interval, CI, 0.5–0.9), peripheral vascular disease 
(SMR, 7.9; 95% CI, 2.9–17.2), pulmonary embolism 
(SMR, 5.7; 95% CI, 2.5–11.3) and even intestinal throm-
bosis causing intestinal vascular insufficiency (SMR, 
12.3; 95% CI, 4.0–28.8) [4]. On the other hand, Swerdlow 
and colleagues reported that the SMR was significantly 
higher for each of the above-mentioned diseases with the 
exception of the ischemic heart disease, whose SMR was 
significantly lower in mosaic and non-mosaic KS, but not 
in men with more than three sex chromosomes [7].
After excluding previous or current cardiovascular, 
respiratory and renal chronic diseases, Pasquali and col-
leagues analyzed 69 KS [48 of them had already started 
testosterone replacement therapy (TRT) while the 
remaining 21 were TRT-naïve] and 48 age-matched con-
trols with comparable physical activity and Body Mass 
Index (BMI). The results of this study showed that KS 
patients had a wide array of cardiovascular abnormalities, 
including left ventricular diastolic dysfunction, reduced 
maximal oxygen consumption, increased intima-media 
thickness (IMT) and a high prevalence of chronotropic 
incompetence. All these abnormalities, including pre-
clinical alterations that may forecast future cardiovascu-
lar events, were recognized as independent predictors of 
long-term poor outcome [11].
Table 1  Main comorbidities 
present in men with Klinefelter 
syndrome
SMR standardized mortality rate, CI confidence interval
Pathology SMR (95% CI) Main manifestations
Cardiovascular diseases 1.3 (1.1–1.5) Left ventricular diastolic dysfunction
Decreased maximal oxygen consumption
Increased intima-media thickness
Chronotropic incompetence
Congenital anomalies
Thrombosis/leg ulcers
Cerebrovascular diseases 2.2 (1.6–3.0) Subarachnoid hemorrhage
Intracerebral hemorrhage
Cerebrovascular thrombosis
Arteriovenous malformation
Metabolic disorders 4.8 (2.9–7.4) Obesity
Insulin resistance and hyperinsulinemia
Hyperlipidaemia
Metabolic syndrome
Diabetes
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Klinefelter syndrome and cerebrovascular risk
As for morbidity and mortality risk arising from cerebro-
vascular diseases or congenital malformations, KS patients 
have a significant increase of cerebrovascular diseases, 
and in particular, subarachnoid hemorrhage. Indeed, Price 
and colleagues reported that the deaths due to cerebrovas-
cular diseases were strikingly increased in patients with 
KS of any age (25–84 years), whereas the rupture of a 
berry aneurysm was identified as the third cause of death 
in KS patients with an age range of 25–44 years [10]. On 
the other hand, Swerdlow and colleagues concluded that 
mortality for cerebrovascular disease was significantly 
increased (SMR 2.2; 95% CI, 1.6–3.0). However, it is not 
clear whether the cause of the death certificates for cerebro-
vascular disease is of thrombotic or hemorrhagic nature; 
in the cohort of Swerdlow and colleagues, six deaths were 
due to subarachnoid hemorrhage, four to other intracer-
ebral hemorrhage, and nine to cerebrovascular occlusion or 
thrombosis. In addition, the study confirmed a higher SMR 
for subarachnoid hemorrhage, but generalized atheromasia 
is unlikely to be the explanation for the raised risk, consid-
ering the significantly reduced SMR reported for ischemic 
heart disease [7]. This evidence disagrees with another 
study [6], which showed no association between cerebral 
hemorrhage and KS. Finally, a case of a 12-year-old boy 
with KS who had acute cerebellar hemorrhage due to an 
arteriovenous malformation in the right cerebellar hemi-
sphere was reported; he had bilateral thumb polydactyly 
and patent ductus arteriosus [12].
Klinefelter syndrome and cardiovascular 
congenital anomalies
Cardiovascular congenital anomalies are more frequent 
in patients with KS than in the general population (SRM 
7.3; 95% CI, 2.4–17.1) [7]. Fricke and colleagues reported 
a higher prevalence of mitral valve prolapse, a condition 
associated with an increased risk of sudden death [13]. 
Many case reports have strengthened the relevance of 
detecting cardiac abnormalities by echocardiography and 
peripheral districts echography in KS patients. Acute mitral 
regurgitation by idiopathic chordal rupture [14], hypoplasia 
of the bilateral internal carotid arteries and dilatation of the 
bilateral vertebral arteries with weakness of the limbs [15], 
hypertrophic cardiomyopathy [16], atrial septal defects, 
ventricular septal defects, partial anomalous pulmonary 
venous connection with pulmonary arterial hypertension 
[17] have been reported in patients with KS. Moreover, 
patients with KS, as well as men with Down syndrome, 
have a higher prevalence of atrial septal and ventricular 
septal defects with patent ductus arteriosus, pulmonary 
hypertension and mild tricuspid regurgitation [18], infec-
tive endocarditis associated with valve prolapse and severe 
mitral regurgitation [19], hypertrophic cardiomyopathy and 
mesenteric venous thrombosis [20]. Finally, Karagoz and 
colleagues described a 22-year-old KS patient who had 
bradycardia and syncope because of a sinus node dysfunc-
tion requiring a permanent pacemaker implantation [21].
Little information is available about the nature of the 
underlying cardiovascular abnormalities. Foresta and col-
leagues analyzed the structure and the function of arteries 
in different districts to search for possible abnormalities. 
Ninety-two patients with non-mosaic KS and 50 age-
matched healthy male controls were studied. KS patients 
and controls evaluation included complete anamnesis, 
physical examination, measurement of reproductive hor-
mone concentrations, lipid and glycemic metabolism, 
androgen receptor function and sensitivity, ultrasound 
examinations of several vascular districts (brachial, com-
mon carotid and common femoral artery, abdominal aorta). 
The results of this study showed that patients with KS had 
significantly reduced artery diameters in different districts 
(brachial, common carotid and common femoral artery). 
No statistically significant correlation was found between 
artery diameter and reproductive hormones, metabolic 
parameters, anthropometric measures and CAG repeats 
of the androgen receptor gene [22]. However, it cannot 
be excluded that the increased mortality for different car-
diovascular factors may originate from thromboembolic 
events, related to an abnormality in fibrinolysis in these 
patients (see “Klinefelter syndrome and thrombosis/leg 
ulcers” section).
Klinefelter syndrome and thrombosis/leg ulcers
Patients with KS have an increased risk of developing throm-
bosis or leg ulcers, even in the absence of any triggering 
event. Moreover, as many case reports have shown, this risk 
can be worsened by the co-existence of one or more throm-
bophilic conditions, such as obesity, hypertension, diabe-
tes, that are more frequent in KS, although these conditions 
there are not the only causes. The association between KS 
and thrombophilic conditions is characterized by a worse 
outcome. Lapecorella and colleagues reported the case of a 
39-year old patient with KS who underwent a severe deep 
venous thrombosis with pulmonary embolism in the absence 
of any triggering event. This condition was associated with 
double heterozygosis for G20210A prothrombin and Leiden 
factor V mutations [23]. Indeed, different examples of throm-
bosis and leg ulcer due to various mechanisms are reported 
in the literature. Some cases of recurrent leg ulcers, associ-
ated with immunological disorders (positive antinuclear fac-
tor, antiphospholipid antibodies and cryoglobulins) without 
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venous insufficiency, have recovered after TRT [24]. Accord-
ing to this evidence, Goto and colleagues described two cases 
of patients with KS and systemic lupus erythematotus (SLE) 
(positive lupus anticoagulant) affected by leg ulcers in whom 
TRT improved wound healing [25].
Finally, the case of a KS patient with mixed connective 
tissue disease (Sharp’s syndrome) is present in the litera-
ture [26]. It should be taken into account that some patients 
with KS may suffer from different coagulation abnormali-
ties that underpin the risk of ulceration. These include 
hyperactivity of factor VIII coagulant [27] and the pres-
ence of homozygous mutation for the A1298C factor of the 
methylenetetrahydrofolate reductase (MTHFR) gene [28]. 
Finally, refractory chronic venous leg ulcers have been 
reported by Gattringer and colleagues in two men with 
sex chromosome aberrations (47,XXY/48,XXXY) and in 
a patient with Jacob syndrome (47,XYY). Among them, 
patients with karyotype 47,XXY/48,XXXY, although had 
hypogonadism, showed normal PAI-1 activity [29].
Elevated activity of plasminogen activator inhibitor-1 
(PAI-1), causing alterations in platelet aggregability and 
fibrinolysis, has been documented in patients with KS and 
leg ulceration without underlying venous insufficiency 
[30]. To ascertain whether increased PAI-1 activity is a 
general feature of KS, or more specifically associated with 
leg ulceration, Zollner and colleagues investigated the 
parameters influencing PAI-1 activity in KS patients with 
(n = 7) or without (n = 6) leg ulcerations. By analyzing 
those parameters, such as age, body mass index, triglyc-
erides, C-reactive protein, testosterone, cigarette smoking 
habit, presence of diabetes mellitus, and arterial hyper-
tension, no statistically significant differences were found 
between the two groups, although PAI-1 activity turned 
to be elevated in KS patients with leg ulcers. Since PAI-1 
activity elevation might play a crucial role in the pathogen-
esis of leg ulceration in KS subjects, the treatment should 
include a strategy aimed to reduce PAI-1 activity until 
PAI-1 normal serum levels are achieved [31]. In a recent 
study, twenty-three consecutive KS patients under testos-
terone replacement therapy were included in a case control 
study to evaluate platelet reactivity and the expression of 
platelet activation markers (8-iso-prostaglandin F2a[8-iso-
PGF2a] and 11-dehydro-thromboxane-B2[11-dehydro-
TXB2]). The authors found increased platelet reactivity in 
KS and no correlation between the percentage of maximal 
aggregability, testosterone and estradiol levels [32].
Testosterone treatment and cardiovascular risk 
in patients with Klinefelter syndrome
Given the growing interest for the relationship between 
serum T deficit and cardiovascular abnormalities, several 
authors have recently conducted a large number of studies 
to evaluate whether this relationship may exist in patients 
with KS. Since the effects of testosterone on its target tis-
sues depends on both its metabolites (5α reduction into 
dihydrotestosterone or aromatization into 17β-estradiol) 
and its receptor, these studies have been carried out to 
verify whether the cardiovascular abnormalities found in 
KS depend on serum T levels, its effect on target tissues or 
both.
Di Mambro and colleagues found that the lower artery 
diameters in different districts (brachial, common carotid, 
common femoral artery and abdominal aorta) of KS 
patients did not relate with low (<10.4 nmol/L) or normal 
(>10.4 nmol/L) serum testosterone levels [33]. In addition, 
flow-mediated dilation (FMD), carotid IMT, AR sensitivity 
and blood pressure did not show any statistically significant 
difference between KS patients with normal or low serum 
T [22]. Finally, no statistically significant difference was 
found in cardiovascular abnormalities between treated and 
untreated KS patients. Consequently, the cardiovascular 
abnormalities are not reversed by TRT, being dependent 
upon KS itself rather than on the patient hormonal condi-
tion. Therefore, cardiovascular abnormalities may represent 
the pathophysiological underpinnings, perhaps induced 
by chromosomal abnormality, of the increased risk of 
death for heart disease [11]. Thus, early diagnosis of KS is 
important to start TRT as soon as possible [34] to avoid the 
onset of androgen deficiency symptoms [35], but not the 
other features related to the genetic abnormality [36]. Some 
studies suggest that men with KS should start TRT during 
puberty with a target testosterone level in the higher part 
of the normal range, but there are no randomized placebo-
controlled studies to support this approach [37]. Therefore, 
the efficacy of precocious versus delayed TRT to prevent 
cardiovascular risk is not known.
Testosterone replacement therapy and circulating 
endothelial progenitor cells or endothelial 
microparticles in patients with Klinefelter 
syndrome
A reduced number of circulating endothelial progeni-
tor cells (EPCs) is an independent predictor of morbidity 
and mortality for cardiovascular diseases. Di Mambro and 
colleagues [33] evaluated EPCs in 68 KS patients and 46 
healthy men, subdivided in two groups according to the 
absence or presence of cardiovascular risk factors (CRFs). 
Controls without CRFs had significantly higher levels of 
EPCs than controls with CRFs; on the contrary, KS patients 
without CRFs had similar levels of EPCs compared to KS 
patients with risk factors and significantly lower levels than 
controls without CRFs. Moreover, the number of EPCs in 
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hypogonadal and eugonadal patients was not significantly 
different. Twenty-two hypogonadal patients were re-evalu-
ated after 6 months of TRT, but the results did not show 
modifications in the number of EPCs. These findings sug-
gest that factors involved in KS (CRFs or other genetically 
determined factors related to the supernumerary X chromo-
some) may contribute to a reduction in EPCs number that 
could lead to a further increase in mortality rates of these 
patients [33].
Condorelli and colleagues, aiming at evaluating the 
effects of TRT on the sexual function, prescribed testoster-
one to a group of 35 middle-aged TRT-naïve hypogonadal 
patients, consisting of 20 patients with acquired prepu-
bertal hypergonadotropic hypogonadism (HrHy), and of 
15 age- and BMI-matched KS patients. After 6 months of 
TRT, patients with HrHy had significantly higher mean 
IIEF-5 score and cavernousal artery peak systolic veloc-
ity and a significantly lower mean acceleration time than 
patients with KS. In addition, patients with HrHy showed 
significantly lower mean apoptotic endothelial micropar-
ticles (EMPa) values and vitronectin receptor (VR) serum 
concentrations than patients with KS. These latter subjects 
showed, after TRT, a significant improvement of IIEF-5 
scores and Doppler parameters, but not of EMPa or VR 
serum concentrations. These results, in agreement with 
other studies, suggest that TRT does not improve the sever-
ity of endothelial cell apoptosis in KS patients [38].
Body composition, metabolic syndrome 
and diabetes mellitus type 2 in Klinefelter patients
There is a growing clinical and scientific interest for the 
metabolic disorders in patients with KS. Both in adoles-
cence and, especially, in adulthood, these patients may 
have different metabolic diseases ranging from obesity and 
metabolic syndrome (MetS) to overt type 2 diabetes melli-
tus (T2DM). Several observational studies, published in the 
last 40 years, have highlighted a close association between 
KS, metabolic diseases and T2DM. Moreover, these meta-
bolic diseases, in association with other important disor-
ders (such as lung and cerebrovascular diseases, thrombotic 
events, and osteoporosis), contribute in increasing mortal-
ity of patients with KS [5, 32].
Recently, a study including 89 prepubertal boys with KS 
showed that about 10% of them have MetS, and more than 
24% have insulin resistance [39]. In addition, many patients 
with KS, even before puberty, have an altered body com-
position characterized by an increased body fat, especially 
in the truncal region, with a reduction in lean body mass. 
Therefore, these patients have lower muscle strength [40, 
41]. The multivariate analysis showed that the truncal fat 
distribution is the most important factor leading to insulin 
resistance and MetS, independently of serum testosterone 
levels [42].
In adult KS patients, several studies have shown an 
elevated prevalence of MetS (diagnosed by the National 
Cholesterol Education Program criteria), hyperlipidaemia 
(especially hypertriglyceridaemia) insulin resistance and 
hyperinsulinemia, and even overt T2DM [42–44]. These 
patients have an increased cardiovascular risk that cannot 
be only referred to these metabolic conditions, but also, 
at least in part, to an increased platelet activity [32]. Con-
versely, blood hypertension is not a frequent finding in 
patients with KS as recently reported [11].
It is not entirely clear the predisposition in patients with 
KS to metabolic diseases, insulin resistance and unbal-
anced body composition is a consequence of a specific 
gene expression pattern, the hormonal status or both in 
patients with KS. It is generally accepted that low serum 
testosterone levels predict the development of abdominal 
obesity and MetS in men independently from chromosomal 
disorders [45, 46]. A meta-analysis including different 
cross-sectional studies, 850 subjects with T2DM and 2900 
healthy men, showed that serum testosterone levels were 
significantly lower in T2DM men even after standardiza-
tion for BMI, waist to hip ratio and age [47]. On the other 
hand, weight loss consequent to hypocaloric diet regimen 
and lifestyle changes, improved serum testosterone levels 
as well as the metabolic disorders in obese men [48].There 
is some evidence that testosterone itself may have a direct 
effect on insulin sensitivity. Indeed, TRT discontinuation 
in patients with central hypogonadism led to insulin resist-
ance within a couple of weeks [49]; while during a 1-week 
hyperinsulinemic-euglycemic clamp, the treatment of 
healthy not obese men with aromatase inhibitor (letrozole) 
resulted in an increase of serum testosterone slightly above 
the physiological levels and in an improvement of insulin 
sensitivity [50]. Furthermore, a recent meta-analysis of ran-
domized controlled studies showed that TRT in eugonadal 
or hypogonadal (testosterone <350  mg/dl) patients, espe-
cially in younger men and in those with metabolic diseases, 
is able to improve metabolic parameters, such as glycaemia 
and insulin resistance, and to reverse body composition by 
both lowering the fat mass and increasing the lean one [51, 
52]. Nevertheless, although several findings show a close 
relationship between serum testosterone levels and meta-
bolic disease, in patients with KS, despite TRT, no conclu-
sive data can be drawn on body composition and metabolic 
control. In fact, Aksglaede and colleagues showed that 
TRT alone only partially corrects the unfavorable muscle/
fat ratio, suggesting that the unfavorable metabolic profile 
found in adult patient with KS may already be present in 
childhood [41]. On the other hand, a group of ten obese KS 
patients with T2DM and erectile dysfunction was able to 
lose weight, to reach the metabolic control, and to improve 
710 J Endocrinol Invest (2017) 40:705–712
1 3
erectile dysfunction only by a combination therapy made 
up of testosterone, metformin and liraglutade (a glucagon-
like peptide-1 agonist) [53].
Since the body composition is already unbalanced in 
favor to the adipose component in pubertal and adolescent 
KS boys, other causes beyond the testosterone deficiency 
should be taken into account. Different genetic anomalies 
have been hypothesized as possible causes of the altered 
body composition in these patients by several authors. In 
particular, the over-expression of X-linked genes, skewed X 
chromosome inactivation, transcriptional dysregulation of 
apoptosis cascade, glucose metabolism and inflammation 
genes or CAG repeat polymorphism of the AR (all of them 
mapping on the X chromosome)  may be involved in this 
process [54, 55]. Finally, Rotondi and colleagues showed 
that MetS is associated with a low-grade chronic inflam-
matory status characterized by abnormal cytokine produc-
tion. CCL2, produced by monocytes, dendritic cells and 
macrophages, induces chronic low-grade inflammation by 
accelerating macrophage infiltration in adipose tissue and 
its overproduction is associated with insulin resistance [56]. 
Men with KS had increased CCL2 circulating levels and 
the authors found a direct correlation between CCL2 and 
testosterone levels [56]. Hence, further studies are needed.
Conclusions
Patients with KS have an increased morbidity and mortal-
ity that can be due to ischemic heart disease, cerebrovas-
cular diseases (e.g., subarachnoid hemorrhage), thrombosis 
of the deep veins (e.g., pulmonary embolism and intestinal 
thrombosis) and leg ulcer. In addition, KS patients have an 
increased prevalence of metabolic disease (obesity, meta-
bolic syndrome and T2DM) diseases that contribute to the 
increased morbidity and mortality rates in these patients.
Several studies have shown a relationship between the 
deficit of testosterone, metabolic diseases and cardiovascu-
lar risk in patients with KS. The role of the additional X 
chromosome and the dysregulation of different genes map-
ping on this chromosome may be involved in this associa-
tion. Unfortunately, there is no definitive evidence on the 
effect of TRT on metabolic diseases, body composition 
and markers of cardiovascular risk, such as serum PAI-1, 
EPCs number and carotid IMT, in these patients. Indeed, in 
case of important metabolic disorders, such as T2DM with 
insufficient metabolic control and obesity, the combination 
of two drugs effective in lowering blood glucose and body 
weight, should be prescribed to reach a good metabolic 
control and the weight loss.
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